歌禮制藥-B(01672.HK):中期總收入4650.6萬元 同比增加21.7%
格隆匯8月22日丨歌禮制藥-B(01672.HK)發佈公吿,截至2023年6月30日止六個月,集團的總收入同比增加21.7%至約人民幣4650.6萬元。集團毛利同比增加58.5%至約人民幣3862萬元,主要由於收入增加人民幣830萬元,較2022年同期相比增長21.7%及生產成本控制的改善。於2023年6月30日,集團的現金及銀行結餘約為人民幣25.129億元(2022年6月30日:約人民幣24.837億元),其預計足以支持其直至2027年的研發活動及運營。
集團建立了一個覆蓋廣泛的資產管線,專注於病毒性疾病、非酒精性脂肪性肝炎╱PBC及腫瘤領域。於報吿期內及直至本公吿日期,集團成功取得美國FDA和中國國家藥監局的五項IND批准,完成了一項I期及兩項II期試驗並支持了5項正在進行的II期或III期的候選藥物的臨牀開發。這種研發效率再次體現了與中國生物科技行業的同業相比集團卓越的運營水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.